Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Public ClinicalTrials.gov record NCT03078075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NIDA (National Institute on Drug Abuse) CTN (Clinical Trials Network) Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.
Study identification
- NCT ID
- NCT03078075
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 403 participants
Conditions and interventions
Conditions
Interventions
- Naltrexone: Vivitrol® Drug
- Placebo (PLB) Injectable Drug
- Bupropion: Wellbutrin XL® Drug
- Placebo (PLB) Oral Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2017
- Primary completion
- Jul 2, 2019
- Completion
- Jul 24, 2019
- Last update posted
- May 2, 2021
2017 – 2019
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles (UCLA) Center for Behavioral Addiction Medicine (CBAM) | Los Angeles | California | 90038 | — |
| Substance Use Research Unit (SURU) at the San Francisco Dept. of Public Health | San Francisco | California | 94102 | — |
| Hennepin County Medical Center- Berman Center for Research | Minneapolis | Minnesota | 55415 | — |
| New York State Psychiatric Institute (NYSPI)- Substance Use Research Center (SURC) | New York | New York | 10032 | — |
| CODA, Inc. | Portland | Oregon | 97214 | — |
| Behavioral Health Services (BHS) of Pickens County | Pickens | South Carolina | 29671 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235 | — |
| University of Texas Health Science Center - Center for Neurobehavioral Research on Addiction (CNRA) | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03078075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2021 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03078075 live on ClinicalTrials.gov.